Next Article in Journal
Negative Cellular Effects of Urban Particulate Matter on Human Keratinocytes Are Mediated by P38 MAPK and NF-κB-dependent Expression of TRPV 1
Next Article in Special Issue
Molecular Mechanisms of H. pylori-Induced DNA Double-Strand Breaks
Previous Article in Journal
Comparative Transcriptomics Identifies Novel Genes and Pathways Involved in Post-Traumatic Osteoarthritis Development and Progression
Previous Article in Special Issue
Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(9), 2659; https://doi.org/10.3390/ijms19092659

What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

1
Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
2
Division of GI Tract Surgical Oncology, Department of Cardio-Thoracic and Respiratory Sciences, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
*
Authors to whom correspondence should be addressed.
Received: 18 August 2018 / Revised: 3 September 2018 / Accepted: 5 September 2018 / Published: 7 September 2018
(This article belongs to the Special Issue Molecular Features Distinguishing Gastric Cancer Subtypes)
Full-Text   |   PDF [287 KB, uploaded 7 September 2018]

Abstract

Despite some remarkable innovations and the advent of novel molecular classifications the prognosis of patients with advanced gastric cancer (GC) remains overall poor and current clinical application of new advances is disappointing. During the last years only Trastuzumab and Ramucirumab have been approved and currently used as standard of care targeted therapies, but the systemic management of advanced disease did not radically change in contrast with the high number of molecular drivers identified. The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) classifications paved the way, also for GC, to that more contemporary therapeutic approach called “precision medicine” even if tumor heterogeneity and a complex genetic landscape still represent a strong barrier. The identification of specific cancer subgroups is also making possible a better selection of patients that are most likely to respond to immunotherapy. This review aims to critically overview the available molecular classifications summarizing the main druggable molecular drivers and their possible therapeutic implications also taking advantage of new technologies and acquisitions. View Full-Text
Keywords: gastric cancer; molecular classifications; targeted therapy; immunotherapy gastric cancer; molecular classifications; targeted therapy; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Tirino, G.; Pompella, L.; Petrillo, A.; Laterza, M.M.; Pappalardo, A.; Caterino, M.; Orditura, M.; Ciardiello, F.; Galizia, G.; De Vita, F. What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. Int. J. Mol. Sci. 2018, 19, 2659.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top